Preview

Российский кардиологический журнал

Расширенный поиск

ВОЗМОЖНОСТИ СНИЖЕНИЯ СЕРДЕЧНО-СОСУДИСТЫХ РИСКОВ У ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА

https://doi.org/10.15829/1560-4071-2017-9-99-103

Полный текст:

Аннотация

.

Об авторе

статья Редакционная

Россия


Список литературы

1. IDF Diabetes Atlas. 6-th edition. 20166. Available from: http://www.idf.org/diabetesatlas

2. www.who.int

3. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151: 1141-7.

4. Neaton JD, Wentworth DN, Cutler J, Kuller L. Risk factors for death from different types of stroke. Multiple Risk Factor Intervention trial Research Group. Ann Epidemiol 1993; 3: 493-9.

5. IDF diabetes atlas. 7th ed. Brussels: International Diabetes Federation, 2015.

6. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U. S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.

7. Haffner SM, Lehto S, Ronnemaa T. Mortality from coronary artery disease in subject with type 2 diabetes and nondiabetic subjects with and without myocardial infarction. N Engl J Med 1998; 339: 229-34

8. The Task Force on Diabetes and cardiovascular Disease of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Gidelines on diabetes, pre-diabetes, and cardiovascular disease: executive summary. Eur Heart J 2007; 28: 464-6.

9. The structure of morbidity and mortality in Russian Federation in 2004. Klinicheskaia meditsina. 2005; 1: 3-8. (In Russ.) (Структура сердечно-сосудистой заболеваемости и смертности в РФ за 2004 г. Клиническая медицина. 2005; 1: 3-8).

10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.

11. Ryden L, Grant PJ, Zamorano JL, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Russian Journal of Cardiology. 2014; 3 (107): 7-61. (In Russ.) (Ryden L, Grant PJ, Zamorano JL, et al. Рекомендации по диабету, предиабету и сердечно-сосудистым заболевани- ям. EASD/ESC. Российский кардиологический журнал 2014, 3 (107): 7-61). DOI: 10.15829/1560-4071-2014-3-7-61

12. Nathan DM, Buse JB, Davidson MB, et al., for the American Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustments of therapy: a consensus statement of the American Diabetes Association and the European Association for Study of Diabetes. Diabetes Care 2009; 32: 193-203.

13. Wajchenberg BL. β-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28: 187-218.

14. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65 (published correction appears in Lancet 1998; 352: 1558).

15. Kahn SE, Haffner SM, Heise MA, et al., for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43 (published correction appears in N Engl J Med 2007; 29: 356).

16. Davis TM, Cull CA, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: UK Prospective Diabetes Study (UKPDS 55). Diabetes Care 2001; 24: 1167-74.

17. Gerstein HC, Miller ME, Byington RP, et al., for the Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Eng J Med 2008; 358: 2545-59.

18. Riddle MC, Rosenstock J, Gerich J, for the Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine of human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-86.

19. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 2016; 18: 203-16.

20. Du Q, Wang YJ, Yang S, Zhao YY, Han P. Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Adv Ther 2014; 31: 1182-95.

21. Robinson LE, Holt TA, Rees K, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013; 3.

22. Davies MJ, Bain SC, Atkin SL, et al. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care 2016; 39 (2): 222-30.

23. Zavattaro M, Caputo M, et al. One-year treatment with liraglutide improved renal functionin patients with type 2 diabetes: a pilot prospective study. Endocrine 2015; 50 (3): 620-6.

24. Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes, N Engl J Med 2016; 375: 311-22.

25. www.siditalia.it/news/1229-26-07-2016-position-statement-sid-farmaci-ipoglicemizzantimalattie-cardiovascolari-e-renali

26. Arbeitsgruppe der SGED/SSED R. Lehmann (Vorsitz), T. Bianda, M. Brändle, A. Czock, M. Egli, J. Philippe, C. Stettler, S. Thalmann, T. Weng. Empfehlungen der SGED/SSED: Massnahmen zur Blutzuckerkontrolle bei Patien-ten mit Diabetes mellitus Typ 2. http:// sgedssed.ch/fileadmin/files/6_empfehlungen_fachpersonen/61_richtlinien_fachaerzte/ SGED_Empfehlung_BZ-Kontrolle_T2DM_Finale_Version_12_korr_17.10.16.pdf

27. Nasjonal faglig retningslinje for diabetes. Nasjonal faglig retningslinje for diabetes Sist oppdatert 20.9.2016. https://www.google.ru/url?sa=t&rct=j&q=&esrc=s&source=web&c d=8&ved=0ahUKEwiFjdXg7IjVAhUoDZoKHRKCAR8QFghVMAc&url=https%3A%2F%2Fmi tt.uib.no%2Fcourses%2F1966%2Ffiles%2F213291%2Fdownload%3Fdownload_frd%3D 1&usg=AFQjCNGKGkmUfeZtHrmv41XGmwYnNk7VBw&cad=rjt

28. Policies, Guidelines, and Consensus Statements Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Can J Diabetes 2016; 40: 484-6.

29. Landgraf R, Kellerer M, et al. Deutscher praxisempfehlungen DDg/DGIM Theraspie des Tip-2-Diabetes. Diabetologie 2016; 11 (Suppl 2): S117-29.

30. American Diabetes Association Standards of Medical Care in Diabetes, 2017. Diabetes Care 2017; 40 (Suppl 1): 1-142.

31. Clinical guidelines. Algorithms of special medical assistance for diabetes patients. Eds. Dedov II, Shestakova MV, Majorova AYu. Sakharny Diabet 2017; 20 (1S): 1-112. (In Russ.) (Клинические рекомендации “Алгоритмы специализированной медицинской помощи больным сахарным диабетом”, под ред. Дедова И.И., Шестаковой М.В., Майорова А.Ю. Сахарный диабет 2017; 20 (1S): 1-112).

32. Dedov II, Shestakova MV, Benedetti MM, et al. Prevalence of Type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Research and Clinical Practice 2016; 115: 90-5.


Для цитирования:


ВОЗМОЖНОСТИ СНИЖЕНИЯ СЕРДЕЧНО-СОСУДИСТЫХ РИСКОВ У ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА. Российский кардиологический журнал. 2017;(9):99-103. https://doi.org/10.15829/1560-4071-2017-9-99-103

For citation:


THE POSSIBILITY OF REDUCING CARDIOVASCULAR RISK IN PATIENTS WITH DIABETES MELLITUS TYPE 2. Russian Journal of Cardiology. 2017;(9):99-103. (In Russ.) https://doi.org/10.15829/1560-4071-2017-9-99-103

Просмотров: 815


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)